Prognostic impact of serum transthyretin in patients with non‑small cell lung cancer

  • Authors:
    • Tatsuo Shimura
    • Masahiko Shibata
    • Takuya Inoue
    • Yuki Owada‑Ozaki
    • Takumi Yamaura
    • Satoshi Muto
    • Takeo Hasegawa
    • Yutaka Shio
    • Hiroyuki Suzuki
  • View Affiliations

  • Published online on: April 3, 2019     https://doi.org/10.3892/mco.2019.1837
  • Pages: 597-604
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The identification of novel biomarkers is of great importance for improving the outcome of patients with non‑small cell lung cancer (NSCLC). Therefore, the aim of the present study was to determine whether the serum transthyretin (TTR) level could be used as a novel prognostic biomarker for patients with NSCLC. Serum TTR levels, and nutritional and inflammatory parameters were examined prior to treatment in 42 patients with NSCLC. Candidates for independent predictors of prognostic factors were subjected to univariate and multivariate analyses using a Cox proportional hazard model. IL‑12‑productivity, serum retinol binding protein, albumin and transferrin levels, and lymphocyte‑to‑monocyte ratio were significantly lower in the patients with TTR <22 mg/dl than those in the patients with TTR ≥22 mg/dl. Patients with serum TTR levels of <22 mg/dl exhibited a poorer overall (P=0.008) and recurrence‑free survival (P=0.027) when compared with those with serum TTR levels of ≥22 mg/dl. The parameters, ≥T2 and age ≥75 years were independent prognostic factors for overall survival, and TTR <22 mg/dl and ≥T2 were independent prognostic factors for recurrence‑free survival. In conclusion, anthropometric measurement of serum TTR, as well as T category, can be useful for predicting the 5‑year recurrence‑free survival of patients with NSCLC.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 10 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Shimura, T., Shibata, M., Inoue, T., Owada‑Ozaki, Y., Yamaura, T., Muto, S. ... Suzuki, H. (2019). Prognostic impact of serum transthyretin in patients with non‑small cell lung cancer. Molecular and Clinical Oncology, 10, 597-604. https://doi.org/10.3892/mco.2019.1837
MLA
Shimura, T., Shibata, M., Inoue, T., Owada‑Ozaki, Y., Yamaura, T., Muto, S., Hasegawa, T., Shio, Y., Suzuki, H."Prognostic impact of serum transthyretin in patients with non‑small cell lung cancer". Molecular and Clinical Oncology 10.6 (2019): 597-604.
Chicago
Shimura, T., Shibata, M., Inoue, T., Owada‑Ozaki, Y., Yamaura, T., Muto, S., Hasegawa, T., Shio, Y., Suzuki, H."Prognostic impact of serum transthyretin in patients with non‑small cell lung cancer". Molecular and Clinical Oncology 10, no. 6 (2019): 597-604. https://doi.org/10.3892/mco.2019.1837